Thomas King, MS, MPH

Single-Dose Pharmacokinetics of Amphetamine Extended-Release Tablet (AMPH ER TAB) Compared With Amphetamine Extended-Release Oral Suspension (AMPH EROS)

OBJECTIVES: Evaluate bioavailability of single-dose amphetamine extended-release tablet (AMPH ER TAB) 20 mg, swallowed whole/chewed and amphetamine extended-release oral suspension (AMPH ...

Thomas King , MS, MPH;

Antonio Pardo , MD;

Barry Herman , MD, MMM;

11/22/2019

Palatability Assessment of a New Amphetamine Extended-Release Tablet Formulation

Background Palatability is a positive factor in adherence and persistence with prescribed medication regimens. We assessed palatability for a new amphetamine extended-release tablet (Dya...

Judith Kando , PharmD, BCPP;

Thomas King , MS, MPH;

Antonio Pardo , MD;

Eman Rafla ;

10/08/2020

A Novel, Modified Release Drug Delivery Technology Containing Amphetamine-Ion Exchange Complexes

The proprietary immediate+extended drug delivery technology LiquiXR™ utilizes an ion-exchange resin that complexes with any protonated, water-soluble active moiety. The active drug comple...

Thomas King , MS, MPH;

Antonio Pardo , MD;

Judith Kando , PharmD, BCPP;

11/22/2019

Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension (AMPH EROS) in the Treatment of Children With Attention-Deficit/Hyperactivity Disorder

Objective: Determine if AMPH EROS has an onset of effect at 30 minutes post-dose in children with ADHD.

Antonio Pardo , MD;

Barry Herman , MD, MMM;

Ann Childress , MD;

Thomas King , MS, MPH;

11/22/2019